With the European rollout for Idefirix progressing steadily, Hansa Biopharma AB is now preparing to go stateside and has raised fresh funds for the submission and potential US launch of the kidney transplant drug.
Hansa Grows Cash Pile Ahead of Idefirix US Filing
European Launches Progressing Smoothly
The Swedish biotech has added another $40m to its coffers as it advances its potential ‘pipeline in a product’ for kidney disease.
